Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study Meeting Abstract
| Authors: | Cohen, D. J.; Christos, P. J.; Kindler, H. L.; Catenacci, D. V. T.; Bekaii-Saab, T. B.; Tahiri, S.; Janjigian, Y. Y.; Gibson, M. K.; Chan, E.; Rajdev, L.; Urba, S.; Wade, J. L.; Kozuch, P.; Love, E.; Vandris, K.; Takebe, N.; Hochster, H. S.; Sparano, J. A. |
| Abstract Title: | Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419601386 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.4011 |
| Notes: | Meeting Abstract: 4011 -- Source: Wos |
